IOncology

Editor’s Note: In a recent academic presentation, Prof. Do-Youn Oh (Seoul National University College of Medicine) shared updated long-term results from the Asian subgroup of the Phase III KEYNOTE-859 study,…

Editor’s Note: At a recent GI oncology symposium, Prof. Jung Yong Hong (Samsung Medical Center, South Korea) presented safety results from the Phase 3b SIERRA study, focusing on Asian patients…

Editor’s Note: In an oral presentation selected by the ESMO Asia Scientific Committee, Dr. David Tai (Singapore) presented updated subgroup analyses from the Phase III CheckMate 9DW study, examining the…

Editor’s Note: Despite the success of immune checkpoint inhibitors (ICIs) in GI tumors, immune resistance and the immunosuppressive tumor microenvironment (TME) remain major barriers. At a recent symposium, Prof. Kohei…

Editor’s note: From its early focus on “standards, safety and standardized practice” to today’s deep integration of clinical, basic, and translational research, the 8th Shanghai International Medical Oncology Symposium (SIMOS)…

At the recently concluded European Society for Medical Oncology Asia Congress (ESMO Asia), participating experts shared and reviewed the latest advances in numerous breast cancer clinical studies. Oncology Frontier has…

From December 5 to 7, 2025, the highly anticipated European Society for Medical Oncology Asia Congress (ESMO Asia 2025) was grandly held in Singapore. During the Mini Oral Session: Gastrointestinal Tumours, Professor George Lau, Chairman of the Hong Kong Humanity Medical Group and Director of the Humanity Medical Clinical Research CenterSenior Consultant in Gastroenterology and Hepatology, Humanity and Health Medical Center, Principal Investigator of the Humanity and Health Clinical Trial Center, as well as a physician Honorary Professor and Senior Consultant at Zhongshan Hospital Affiliated to Fudan University, was invited to deliver an oral presentation. For the first time, he shared the research data on the treatment of Asian patients with unresectable hepatocellular carcinoma (HCC) using Tremelimumab in combination with Durvalumab. This study is based on a sample that more closely reflects the epidemiological characteristics and disease spectrum of Asian patients, providing high-quality evidence-based medical evidence with targeted relevance. It lays a solid foundation for optimizing and advancing the individualization and precision of liver cancer treatment strategies in this region.

At the recent ESMO Asia 2025 Congress, a study by Professor Darren Poon's team at the Hong Kong Comprehensive Oncology Centre was selected, bringing a new precision medicine strategy to patients with advanced prostate cancer. Oncology Frontier- UroStream invited Professor Poon to share his insights on the clinical value and future prospects of liquid biopsy for Chinese patients with androgen receptor ligand binding domain-mutated prostate cancer. #ESMOAsia2025 #prostatecancer #precisionmedicine

Editor’s Note: The 20th Shanghai International Breast Cancer Symposium (SIBCS), organized by the Shanghai Anti-Cancer Association and the Breast Cancer Professional Committee of the China Anti-Cancer Association, was held in…

The 20th Shanghai International Breast Cancer Symposium (SIBCS), jointly organized by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was recently held in Shanghai. Under the theme “20 Years of Progress, a Future of Continuity”, the forum brought together leading experts from China and abroad to reflect on two decades of advances in breast cancer diagnosis and treatment in China. During the “Year in Review” session, Professor Feng Jin of the First Hospital of China Medical University delivered a presentation titled “Key Clinical Trial Achievements in Chinese Breast Cancer Research.” Oncology Frontier invited Professor Jin for an in-depth discussion on China’s breakthrough clinical evidence, its global impact, and China’s future developmental directions in breast cancer research.